Redeye updates in EG7 ahead of Q1-results (due May 15) where we expect stable performance from EG7’s...
Q1: Sales 4% below, EBITDA NOK 10m vs ABGSCe NOK 4m NOK 10m lower opex explains beat.
Redeye has updated its estimates following Heliospectra’s Q1 2025 report.
Redeye provides an update following Nitro Games’ Q1 2025 report, which was in line with expectations...
Redeye changes its Base Case and forecasts following a mixed Q1 report from Addnode.
59% y-o-y sales growth for Catalyst in Q1'25e Lower our EBIT forecasts by 12-23% for '25e-'27e Q1'25...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 28 april 2025 att Koncernen förvärv...
Vid en första anblick såg Vaxxas rapport svag ut med totala intäkter om cirka 13 MSEK och en bruttom...
NOI +75% y-o-y and -0.7% vs ABGSCe Value uplift 2.1% q-o-q, net LTV at 48.
We forecast SEK 30m EBIT for Q1e, up 6x vs. Q1'24 ABGSCe EBIT down on reduced activity assumptions &...
Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system.
Stark försäljningsstart med blandad utveckling Acuvi vände trenden och visade försäljningstillväxt e...
Fastpartners hyresintäkter och driftnetto minskade något för det första kvartalet drivet av avyttrin...
Redeye shares its thoughts on today’s news, where the board of directors of Ngenic have decided to f...
Redeye comments on Nitro Games' Q1 2025 report, which came in roughly in line with expectations.
Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025.
Alternative MRI contrast agent for frail cancer patients Ph 3 finished and ready for FDA filing Init...
Limited estimate revisions We expect more solid growth from its own brands Trading at '25e EV/EBITA ...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q1 2025 report, which w...
Redeye maintains a positive view on Dynavox, which delivered another quarter of impressive growth, w...
